Clinical Trials Browser

cemiplimab × Endocrine × 90 days × Clear all

Thyroid Carcinoma, Anaplastic

NCT05142189 2026-04-14

LuCa-MERIT-1

Diabetes Mellitus, Insulin-Dependent, 12, Lethal Congenital Contracture Syndrome 2, Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Multiple Endocrine Neoplasia Type 2a

NCT06900595 2026-04-14

Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer

Phase 2 Recruiting

48 enrolled

Endocrine

Adrenocortical Carcinoma

Clinical Trials

Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid Cancer

LuCa-MERIT-1

Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer